Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species

被引:42
作者
Kapoor, Mili [1 ]
Moloney, Molly [1 ]
Soltow, Quinlyn A. [1 ]
Pillar, Chris M. [2 ]
Shaw, Karen Joy [1 ]
机构
[1] Amplyx Pharmaceut, San Diego, CA 92130 USA
[2] Micromyx, Kalamazoo, MI USA
关键词
APX001; fosmanogepix; APX001A; manogepix; MGX; Gwt1; antifungal; Candida; resistance; BROAD-SPECTRUM ANTIFUNGAL; IN-VITRO ACTIVITY; E1210; CLSI; ALBICANS; SPP;
D O I
10.1128/AAC.01387-19
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Manogepix (MGX) targets the conserved fungal Gwt1 enzyme required for acylation of inositol early in the glycosylphosphatidylinositol biosynthesis pathway. The prodrug fosmanogepix is currently in clinical development for the treatment of invasive fungal infections. We determined that the median frequencies of spontaneous mutations conferring reduced susceptibility to MGX in Candida albicans, C. glabrata, and C. parapsilosis ranged from 3 x 10(-8) to <1.85 x 10(-8). Serial passage on agar identified mutants of C. albicans and C. parapsilosis with reduced susceptibility to MGX; however, this methodology did not result in C. glabrata mutants with reduced susceptibility. Similarly, serial passage in broth resulted in <2-fold changes in population MIC values for C. tropicalis, C. auris, and C. glabrata. A spontaneous V163A mutation in the Gwt1 protein of C. glabrata and a corresponding C. albicans heterozygous V162A mutant were obtained. A C. glabrata V163A Gwt1 mutant generated using CRISPR, along with V162A and V168A mutants expressed in C. albicans and Saccharomyces cerevisiae Gwt1, respectively, all demonstrated reduced susceptibility to MGX versus control strains, suggesting the importance of this valine residue to MGX binding across different species. Cross-resistance to the three major classes of antifungals was evaluated, but no changes in susceptibility to amphotericin B or caspofungin were observed in any mutant. No change was observed in fluconazole susceptibility, with the exception of a single non-Gwt1 mutant, where a 4-fold increase in the fluconazole MIC was observed. MGX demonstrated a relatively low potential for resistance development, consistent with other approved antifungal agents and those in clinical development.
引用
收藏
页数:12
相关论文
共 39 条
[1]   In vitro oligosaccharide synthesis using intact yeast cells that display glycosyltransferases at the cell surface through cell wall-anchored protein Pir [J].
Abe, H ;
Shimma, Y ;
Jigami, Y .
GLYCOBIOLOGY, 2003, 13 (02) :87-95
[2]  
[Anonymous], 2008, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts
[3]  
Third Informational Supplement. CLSI document M27-S3, P28
[4]  
Arendrup MC, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.01225-18, 10.1128/aac.01225-18]
[5]   Activity of novel antifungal compound APX001A against a large collection of Candida auris [J].
Berkow, Elizabeth L. ;
Lockhart, Shawn R. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (11) :3060-3062
[6]   Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision [J].
Bongomin, Felix ;
Gago, Sara ;
Oladele, Rita O. ;
Denning, David W. .
JOURNAL OF FUNGI, 2017, 3 (04)
[7]   Hidden Killers: Human Fungal Infections [J].
Brown, Gordon D. ;
Denning, David W. ;
Gow, Neil A. R. ;
Levitz, Stuart M. ;
Netea, Mihai G. ;
White, Theodore C. .
SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (165)
[8]  
BRYSON V, 1952, SCIENCE, V116, P45, DOI 10.1126/science.116.3003.45
[9]   Activities of E1210 and Comparator Agents Tested by CLSI and EUCAST Broth Microdilution Methods against Fusarium and Scedosporium Species Identified Using Molecular Methods [J].
Castanheira, Mariana ;
Duncanson, Frederick P. ;
Diekema, Daniel J. ;
Guarro, Josep ;
Jones, Ronald N. ;
Pfaller, Michael A. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (01) :352-357
[10]   An adhesin of the yeast pathogen Candida glabrata mediating adherence to human epithelial cells [J].
Cormack, BP ;
Ghori, N ;
Falkow, S .
SCIENCE, 1999, 285 (5427) :578-582